West Pharmaceutical Services (WST) Long-Term Investments (2009 - 2026)

West Pharmaceutical Services has disclosed Long-Term Investments across 18 years of filings, most recently posting $209.2 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $209.2 million, down 1.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $209.2 million (down 1.27% YoY), and the FY2025 annual result was $212.3 million, up 5.05% from the prior year.
• Long-Term Investments came in at $209.2 million for Q1 2026 at West Pharmaceutical Services, down from $212.3 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $224.7 million in Q2 2025 to a low of $188.6 million in Q3 2022.
• The 5-year median for Long-Term Investments is $208.1 million (2022), against an average of $206.5 million.
• Across the five-year window, Long-Term Investments retreated 12.56% in 2022 and advanced 13.37% in 2025, its largest moves.
• West Pharmaceutical Services' Long-Term Investments stood at $204.9 million in 2022, then grew by 2.49% to $210.0 million in 2023, then slipped by 3.76% to $202.1 million in 2024, then climbed by 5.05% to $212.3 million in 2025, then slipped by 1.46% to $209.2 million in 2026.
• The last three Long-Term Investments figures came in at $209.2 million (Q1 2026), $212.3 million (Q4 2025), and $220.9 million (Q3 2025), per Business Quant data.